Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458507080733v1
1352458507080733v2
14/2/219    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Simeoni, M.
Right arrow Articles by Pelletier, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simeoni, M.
Right arrow Articles by Pelletier, J., on behalf
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on March 1, 2008
Multiple Sclerosis, Vol. 14, No. 2, 219-230 (2008)
DOI: 10.1177/1352458507080733
© 2008 SAGE Publications

Validation of the Multiple Sclerosis International Quality of Life questionnaire

MC Simeoni

Department of Public Health, Timone University Hospital, Marseille, France

P. Auquier

Department of Public Health, Timone University Hospital, Marseille, France, pascal.auquier{at}medecine.univ-mrs.fr

O. Fernandez

Hospital Regional Universitario Carlos Haya, Málaga, Spain

P. Flachenecker

Department of Neurology, University of Würzburg, Würzburg, Germany, Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Würzburg, Germany

S. Stecchi

Centro SM, Villa Mazzacorati, Bologna, Italy

CS Constantinescu

Division of Clinical Neurology, University Hospital, University of Nottingham, Nottingham, UK

E. Idiman

Dokuz Eylül Üniversity, Department of Neurology, Izmir, Turkey

A. Boyko

Department of Neurology, Russian State Medical University, Moscow, Russia

AG Beiske

Department of Neurology, Akershus University Hospital, Lørenskog, Norway

T. Vollmer

Van Denburgh Chair, Division of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA

N. Triantafyllou

Department of Neurology, Aiginition Hospital, University of Athens, Greece

P. O'Connor

St Michael's Hospital, University of Toronto, Ontario, Canada

Y. Barak

SHEBA MC, Tel-HaShomer and the Sackler School of Medicine, Tel Aviv, Israel

L. Biermann

P.O. Box 12605, Queenswood, South Africa

E. Cristiano

Department of Neurology, University of Buenos Aires, Head Neurology Hospital Italiano de Buenos Aires, Argentina

S. Atweh

Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon

DL Patrick

Department of Neurology, University of Washington, Seattle, USA

S. Robitail

Department of Public Health, Timone University Hospital, Marseille, France

N. Ammoury

Serono International S.A., Geneva, Switzerland

A. Beresniak

Laboratory of Applied Health Economics LIRAES, University Paris 5, France

J. Pelletier, on behalf of the MusiQol study group

Department of Neurology, Timone University Hospital, Marseille, France

This study aims to validate the Multiple Sclerosis (MS) International Quality of Life (MusiQoL) questionnaire, a multi-dimensional, self-administered questionnaire, available in 14 languages, as a disease-specific quality of life scale that can be applied internationally. A total of 1992 patients with different types and severities of MS from 15 countries were recruited. At baseline and day 21 ± 7, each patient completed the MusiQoL, a symptom checklist and the short-form (SF)-36 QoL questionnaire. Neurologists also collected socio-demographic, MS history and outcome data. The database was randomly divided into two subgroups and analysed according to different patient characteristics. For each model, psychometric properties were tested and the number of items was reduced by various statistical methods. Construct validity, internal consistency, reproducibility and external consistency were also tested. Nine dimensions, explaining 71% of the total variance, were isolated. Internal consistency and reproducibility were satisfactory for all the dimensions. External validity testing revealed that dimension scores correlated significantly with all SF-36 scores, but showed discriminant validity by gender, socio-economic and health status. Significant correlations were found between activity in daily life scores and clinical indices. These results demonstrate the validity and reliability of the MusiQoL as an international scale to evaluate QoL in patients with MS. Multiple Sclerosis 2008; 14: 219—230. http://msj.sagepub.com

Key Words: international • multiple sclerosis • MusiQoL • quality of life • questionnaire • validation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?